Search Results
Your search for Lori J. Pierce, MD, FASTRO, FASCO matches 84 pages
Showing 1 - 50Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past dozen years, many in the oncology community have been profiled in this special issue. A complete list of individuals...
ASCO Congratulates 2024 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2024 ASCO Annual Meeting. The 2024 Special Award Recipients...
Expert Point of View: Lori J. Pierce, MD, FASTRO, FASCO
Despite the lack of long-term follow-up, abstract discussant Lori J. Pierce, MD, FASTRO, FASCO, Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs, University of Michigan, Ann Arbor, underscored the remarkable potential of short-course radiation to transform the...
ASCO Member Testifies Before Congress to Urge Significant Increase in Federal Cancer Research Funding
The Association for Clinical Oncology (ASCO) continues to urge Congress to robustly fund the National Institutes of Health (NIH), National Cancer Institute (NCI), and the Advanced Research Projects Agency for Health (ARPA-H) in Fiscal Year 2024. In testimony submitted to the Senate Committee on...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award recipients at the...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. A complete list of individuals...
ASCO Congratulates 2023 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2023 ASCO Annual Meeting in Chicago. Hear from select award...
President Biden Prioritizes Cancer Research, Access to Care in FY 2024 Budget Proposal
On March 9, 2023, President Joseph Biden released his proposed Fiscal Year (FY) 2024 federal budget, with an emphasis on increased funding for medical research and expanded access to health insurance. The proposal allocates $48.3 billion for the National Institutes of Health (NIH), an $811 million ...
Pilot Program Shows Diversity-Focused Clinical Trial Tools Are Useful at Cancer Research Sites
Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published recently in JCO Oncology Practice.1,2 The studies examine the results from a collaborative...
Expert Point of View: Virginia Kaklamani, MD, Lori J. Pierce, MD, FASTRO, FASCO, and Eric Winer, MD, FASCO
Press briefing moderator Virginia Kaklamani, MD, Professor of Medicine at UT Health San Antonio and leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, said the findings from RxPONDER and those regarding the tumor microenvironment of metastasis (TMEM) doorway are ...
Oncologists Look for Strong Health-Care Priorities in the State of the Union Address
In anticipation of President Joseph R. Biden’s State of the Union Address tonight, ASCO is urging the president to keep cancer care and research as top national priorities. Oncologists have seen how clinical research has improved prevention, detection, and treatment for millions of Americans and...
Nearly All Oncology Providers Report Prior Authorization Causing Delayed Care, Other Patient Harms
Prior authorization is harming individuals with cancer, according to new survey results from ASCO. The survey found that prior authorization delays necessary care, worsens cancer care outcomes, and diverts clinicians from caring for their patients. Nearly all survey participants reported a patient...
Short Course of Radiotherapy With Concurrent Radiation Boost for High-Risk, Early-Stage Breast Cancer
A 3-week course of radiation therapy including a concomitant boost of radiation to the surgical site appears to be as safe and effective as 4 to 6 weeks of radiation therapy given with a sequential boost of radiation for patients with early-stage breast cancer who have a high risk of recurrence....
ASCO Applauds President Biden’s Leadership in Relaunching the Cancer Moonshot
September 12, 2022 “President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored the courage and commitment it would take to accomplish this then-audacious goal: ‘We choose to go to the moon in this decade ...
Diversify Cancer Clinical Trials With New Recruitment and Retention Resources
ASCO and the Association of Community Cancer Centers (ACCC) jointly released two resources to help research sites increase racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials. The Just ASK™ Increasing Diversity in Cancer Clinical Research: An ACCC-ASCO Training...
ASCO Applauds President Biden’s Leadership in Relaunching the Cancer Moonshot
On September 12, Lori J. Pierce, MD, FASTRO, FASCO, Board Chair of the Association for Clinical Oncology (ASCO), made the following statement: “President John F. Kennedy’s historic speech that inspired our nation and an entire generation of Americans to achieve manned space exploration underscored ...
Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot
ASCO recently announced that nine outpatient oncology group practices have achieved certification through the new ASCO Patient-Centered Cancer Care Certification pilot based on their adherence to oncology medical home (OMH) standards, a single set of comprehensive, expert-backed standards for...
How ASCO and ACCC Aim to Increase Diversity in Clinical Trials and Close the Equity Gap in Cancer Care
Research shows that although 15% of Black individuals and 13% of Hispanic individuals have cancer in the United States, only between 4% and 6% of clinical trial participants are Black and between 3% and 6% are Hispanic.1-3 To improve these statistics, in 2020, ASCO and the Association of Community...
ASCO and ACCC Release Joint Recommendations to Increase Equity, Diversity, and Inclusion in Clinical Trials
ASCO and the Association of Community Cancer Centers (ACCC) jointly released recommendations that address the lack of equity, diversity, and inclusion in cancer clinical trials. Published in the Journal of Clinical Oncology,1 their recommendations detail specific actions to engage the entire cancer ...
Narratives in Oncology Through the Years
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community. Over the past years, many in the oncology community have been profiled in this commemorative issue. Here is a complete list of...
Innovation Can Advance Equitable Cancer Care
The North Star of an organization is its mission statement. At ASCO, no initiative gets the green light unless it can fulfill the Society’s mission. ASCO updated its mission statement in 2020 specifically to reinforce our goal of reducing disparities, changing it to read: “Conquering cancer through ...
ASCO and ACCC Release Wide-Ranging Recommendations to Expand Diverse Participation in Cancer Clinical Trials
ASCO and the Association of Community Cancer Centers (ACCC) have jointly released recommendations that address the lack of equity, diversity, and inclusion in cancer clinical trials. Published by Randall A. Oyer, MD, and colleagues in the Journal of Clinical Oncology, the research statement details ...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
Reflecting on the Past 50 Years of Cancer Progress and Looking Ahead to the Next 50 Years of Advances
In December 2021, Nobel laureates, cancer center directors, physicians, scientists, politicians, public health officials, and patient advocates gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to celebrate the 50th anniversary of the signing of the National...
ACCC Presents 2021 Annual Awards for Significant Contributions to Oncology Care
The Association of Community Cancer Centers (ACCC) presented its 2021 Annual Awards at the its 38th National Oncology Conference, held virtually on November 9–10. The awards honor individuals who have made significant contributions to patient care, the practice of clinical care and research, and...
ASTRO Honors 2021 Gold Medalists and Others
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2021 Gold Medal awards and other honors at the 63rd ASTRO Annual Meeting, held October 24 to 27 in Chicago. ASTRO Gold Medal Colleen A.F. Lawton, MD, FASTRO, and Lori J. Pierce, MD, FASTRO, FASCO, received the Gold ...
OlympiA Trial: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early Breast Cancer
Adjuvant therapy with the PARP inhibitor olaparib for 1 year extended disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA1/2 germline (inherited) mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented at the...
With the Exception of Cervical Cancer, HPV-Associated Cancers Are on the Rise, Especially in Older Adults
Although the incidence of cervical cancer has decreased 1.03% a year over the past 17 years in the United States, likely due to screening or vaccination, other human papillomavirus (HPV)-associated cancers are increasing in both men and women, according to a study by Cheng-I Liao, MD, currently of...
OlympiA Trial: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early Breast Cancer
Adjuvant therapy with the PARP inhibitor olaparib for 1 year extended disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA1/2 germline (inherited) mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented at the...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
Study Finds Lower Income Eligibility Limits for Medicaid Associated With Worse Long-Term Survival for Newly Diagnosed Patients With Cancer
A study investigating the association between state Medicaid income eligibility limits and long-term survival among newly diagnosed patients with cancer has found that patients living in states with lower Medicaid income eligibility limits had worse long-term survival compared with patients living ...
Oncology Practices Nationwide Show High Interest in Diversifying Cancer Clinical Trials
ASCO and the Association of Community Cancer Centers (ACCC) recently announced that 75 research sites applied and have been invited to participate in a pilot project testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
ASCO-ACCC Piloting Project to Test Tools to Diversify Cancer Clinical Trials
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, ASCO and the Association of Community Cancer Centers (ACCC) recently announced plans to test a research site assessment tool and implicit bias training...
Watch Now: Discussion on Eligibility Criteria and the Impact on Access to Clinical Trials
On Friday, April 9, 2021, ASCO and Friends of Cancer Research (Friends) co-hosted a live virtual event, which brought together experts from across the health-care sector to discuss the recent release of the new ASCO-Friends recommendations for modernizing eligibility criteria to improve patient...
New ASCO Journal Series Examines Disparities in Cancer Care for Black People in the United States
A new special series in JCO Oncology Practice explores the causes of disparities in cancer care and outcomes for Black people in the United States and examines potential solutions to begin to achieve health equity for this population. The “Disparities in Cancer Care for Black People in the United...
OlympiA Trial: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early Breast Cancer
Adjuvant therapy with the PARP inhibitor olaparib for 1 year extended disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA1/2 germline (inherited) mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented at the...
Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...
OUTBACK Trial: No Survival Benefit With Adjuvant Chemotherapy After Standard Chemoradiation for Locally Advanced Cervical Cancer
Cervical cancer is the fourth most common cancer in women worldwide, and the leading cause of cancer-related death among women in Eastern, Western, Middle, and Southern Africa. Globally, in 2018, approximately 570,000 women were diagnosed with cervical cancer, and 311,000 women died. In the United...
OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer
One year of adjuvant therapy with the PARP inhibitor olaparib extended disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer with BRCA1/2 germline mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented by Andrew Tutt, MB ...
Equitable Cancer Care: Steps Toward Meaningful Change
As President-Elect of ASCO, you are asked to choose a theme for your presidency. This can be a daunting task, as the theme will not only shape the discourse of your presidency, but also, more importantly, that of the Society. The subject should be one that reflects the needs of the cancer community ...
Increased PSA Screening Linked to Lower Risk of Advanced Prostate Cancer at Diagnosis and Death From the Disease in Younger Black Patients
Younger Black men undergoing frequent prostate-specific antigen (PSA) screening appear to have both a lower risk of metastasis at the time of prostate cancer diagnosis and of fatal disease, according to data from an observational study by Qiao et al presented at a presscast in advance of the 2021...
Study Finds Income Eligibility Limits for Medicaid May Be Associated With Worse Long-Term Survival Among Newly Diagnosed Patients With Cancer
A study investigating the association between state Medicaid income eligibility limits and long-term survival among newly diagnosed patients with cancer has found that patients living in states with lower Medicaid income eligibility limits had worse long-term survival compared with patients living...
With the Exception of Cervical Cancer, HPV-Related Cancers Are on the Rise, Especially in Older Adults
Although the incidence of cervical cancer has decreased by 1.03% a year over the last 16 years—likely due to screening or human papillomavirus (HPV) vaccination—other HPV-related cancers are increasing in both men and women, according to a study by Liao et al presented at a presscast in advance of...
Fostering a Global Community of Early-Career Oncologists, Virtually
In a typical year, the new participants in ASCO and Conquer Cancer’s International Development and Education Awards (IDEA) and International Development and Education Awards–Palliative Care (IDEA-PC) program would arrive at the McCormick Place Convention Center just ahead of the ASCO Annual...
Improvement Programs to Optimize Patient Care for Black Americans With Breast Cancer
Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and White Americans have been selected to participate in ASCO’s quality programs, including the Quality Oncology Practice Initiative (QOPI®)and Quality Training Program...
Health-Care Policy Expert Sybil R. Green, JD, RPh, MHA, Brings Wealth of Experience as ASCO’s First Diversity and Inclusion Officer
Sybil R. Green, JD, RPh, MHA, has been named Diversity and Inclusion Officer by ASCO. A health-care policy expert with experience in both corporate and nonprofit organizations, Ms. Green will guide ASCO’s internal and external initiatives aimed at achieving the Society’s equity, diversity, and...
ASCO and Friends of Cancer Research Recommend Expanding Patient Access to Cancer Clinical Trials by Further Broadening Eligibility Criteria
ASCO and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients.1 The joint recommendations are detailed in a series of articles...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
